tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Neovascularization, Pathologic D009389 39 associated lipids
Adenocarcinoma D000230 166 associated lipids
Dermatitis, Contact D003877 59 associated lipids
Bacterial Infections D001424 21 associated lipids
Pain D010146 64 associated lipids
Autoimmune Diseases D001327 27 associated lipids
Lupus Erythematosus, Systemic D008180 43 associated lipids
Genital Diseases, Female D005831 7 associated lipids
Mouth Diseases D009059 5 associated lipids
Meningococcal Infections D008589 3 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Woodward RS et al. Incidence and cost of new onset diabetes mellitus among U.S. wait-listed and transplanted renal allograft recipients. 2003 Am. J. Transplant. pmid:12752315
Lehmann R et al. Successful simultaneous islet-kidney transplantation using a steroid-free immunosuppression: two-year follow-up. 2004 Am. J. Transplant. pmid:15196070
de Fijter JW et al. Early Conversion From Calcineurin Inhibitor- to Everolimus-Based Therapy Following Kidney Transplantation: Results of the Randomized ELEVATE Trial. 2017 Am. J. Transplant. pmid:28027625
Singh K et al. Superiority of rapamycin over tacrolimus in preserving nonhuman primate Treg half-life and phenotype after adoptive transfer. 2014 Am. J. Transplant. pmid:25359003
Dugast E et al. Failure of Calcineurin Inhibitor (Tacrolimus) Weaning Randomized Trial in Long-Term Stable Kidney Transplant Recipients. 2016 Am. J. Transplant. pmid:27367750
Trofe-Clark J et al. Immunosuppression, generic drugs and the FDA. 2012 Am. J. Transplant. pmid:22176626
Latran M Response to Klintmalm on the use of generic immunosuppression. 2012 Am. J. Transplant. pmid:22176636
Ellis CL and Racusen LC Mild rise in creatinine six months post kidney transplant. 2012 Am. J. Transplant. pmid:22845913
Kurtz J et al. Lack of role for CsA-sensitive or Fas pathways in the tolerization of CD4 T cells via BMT and anti-CD40L. 2003 Am. J. Transplant. pmid:12814472
Krenzien F et al. Age-Dependent Metabolic and Immunosuppressive Effects of Tacrolimus. 2017 Am. J. Transplant. pmid:27754593
Borrows R et al. Steroid sparing with tacrolimus and mycophenolate mofetil in renal transplantation. 2004 Am. J. Transplant. pmid:15476485
Hernández-Fisac I et al. Tacrolimus-induced diabetes in rats courses with suppressed insulin gene expression in pancreatic islets. 2007 Am. J. Transplant. pmid:17725683
Hirsch HH et al. Polyomavirus BK replication in de novo kidney transplant patients receiving tacrolimus or cyclosporine: a prospective, randomized, multicenter study. 2013 Am. J. Transplant. pmid:23137180
Mujtaba MA et al. Conversion from tacrolimus to belatacept to prevent the progression of chronic kidney disease in pancreas transplantation: case report of two patients. 2014 Am. J. Transplant. pmid:25179306
Shihab FS et al. Effect of corticosteroid withdrawal on tacrolimus and mycophenolate mofetil exposure in a randomized multicenter study. 2013 Am. J. Transplant. pmid:23167508
Alloway RR et al. A randomized pharmacokinetic study of generic tacrolimus versus reference tacrolimus in kidney transplant recipients. 2012 Am. J. Transplant. pmid:22759200
Wlodarczyk Z et al. Pharmacokinetics for once- versus twice-daily tacrolimus formulations in de novo kidney transplantation: a randomized, open-label trial. 2009 Am. J. Transplant. pmid:19681813
Hesselink DA et al. Cyclosporine interacts with mycophenolic acid by inhibiting the multidrug resistance-associated protein 2. 2005 Am. J. Transplant. pmid:15816878
Byrne GW et al. Warfarin or low-molecular-weight heparin therapy does not prolong pig-to-primate cardiac xenograft function. 2005 Am. J. Transplant. pmid:15816881
Lucey MR et al. A comparison of tacrolimus and cyclosporine in liver transplantation: effects on renal function and cardiovascular risk status. 2005 Am. J. Transplant. pmid:15816894
Pillebout E et al. Renal histopathological lesions after orthotopic liver transplantation (OLT). 2005 Am. J. Transplant. pmid:15816895
Vanrenterghem Y et al. Minimization of immunosuppressive therapy after renal transplantation: results of a randomized controlled trial. 2005 Am. J. Transplant. pmid:15636615
Sindhi R et al. Enhanced donor-specific alloreactivity occurs independently of immunosuppression in children with early liver rejection. 2005 Am. J. Transplant. pmid:15636616
Shergill AK et al. Applicability, tolerability and efficacy of preemptive antiviral therapy in hepatitis C-infected patients undergoing liver transplantation. 2005 Am. J. Transplant. pmid:15636619
Tydén G et al. ABO incompatible kidney transplantations without splenectomy, using antigen-specific immunoadsorption and rituximab. 2005 Am. J. Transplant. pmid:15636623
Woodle ES et al. A multicenter pilot study of early (4-day) steroid cessation in renal transplant recipients under simulect, tacrolimus and sirolimus. 2005 Am. J. Transplant. pmid:15636625
Mian AN et al. Mycoplasma hominis septic arthritis in a pediatric renal transplant recipient: case report and review of the literature. 2005 Am. J. Transplant. pmid:15636628
Gregoor PS and Weimar W Tacrolimus and pure red-cell aplasia. 2005 Am. J. Transplant. pmid:15636632
Meier-Kriesche HU and Kaplan B Cyclosporine microemulsion and tacrolimus are associated with decreased chronic allograft failure and improved long-term graft survival as compared with sandimmune. 2002 Am. J. Transplant. pmid:12095048
Tremblay S et al. A Steady-State Head-to-Head Pharmacokinetic Comparison of All FK-506 (Tacrolimus) Formulations (ASTCOFF): An Open-Label, Prospective, Randomized, Two-Arm, Three-Period Crossover Study. 2017 Am. J. Transplant. pmid:27340950
Padiyar A et al. Clinical predictors of proteinuria after conversion to sirolimus in kidney transplant recipients. 2010 Am. J. Transplant. pmid:20055793
Hardinger KL et al. BK-virus and the impact of pre-emptive immunosuppression reduction: 5-year results. 2010 Am. J. Transplant. pmid:20055811
Pondrom S The AJT report. 2008 Am. J. Transplant. pmid:18324976
Fan DM et al. Successful ABO-incompatible living-related intestinal transplantation: a 2-year follow-up. 2015 Am. J. Transplant. pmid:25808777
Hellemons ME et al. Former smoking is a risk factor for chronic kidney disease after lung transplantation. 2011 Am. J. Transplant. pmid:21883906
Mazariegos GV et al. Dendritic cell subset ratio in tolerant, weaning and non-tolerant liver recipients is not affected by extent of immunosuppression. 2005 Am. J. Transplant. pmid:15643991
Knechtle SJ et al. Early and limited use of tacrolimus to avoid rejection in an alemtuzumab and sirolimus regimen for kidney transplantation: clinical results and immune monitoring. 2009 Am. J. Transplant. pmid:19344431
Bahra M et al. MMF and calcineurin taper in recurrent hepatitis C after liver transplantation: impact on histological course. 2005 Am. J. Transplant. pmid:15644002
Min SI et al. Conversion of twice-daily tacrolimus to once-daily tacrolimus formulation in stable pediatric kidney transplant recipients: pharmacokinetics and efficacy. 2013 Am. J. Transplant. pmid:23734831
Bunnapradist S et al. Conversion from twice-daily tacrolimus to once-daily extended release tacrolimus (LCPT): the phase III randomized MELT trial. 2013 Am. J. Transplant. pmid:23279614
Ceschi A et al. Acute calcineurin inhibitor overdose: analysis of cases reported to a national poison center between 1995 and 2011. 2013 Am. J. Transplant. pmid:23279718
Kaplan B and Kirk AD Tacrolimus and sirolimus: when bad things happen to good drugs. 2006 Am. J. Transplant. pmid:16827845
Vanhove T et al. High Intrapatient Variability of Tacrolimus Concentrations Predicts Accelerated Progression of Chronic Histologic Lesions in Renal Recipients. 2016 Am. J. Transplant. pmid:27013142
Pradhan M et al. Decline in renal function following thoracic organ transplantation in children. 2002 Am. J. Transplant. pmid:12201367
Shapiro R et al. Alemtuzumab pre-conditioning with tacrolimus monotherapy in pediatric renal transplantation. 2007 Am. J. Transplant. pmid:17908272
Rush D et al. Lack of benefit of early protocol biopsies in renal transplant patients receiving TAC and MMF: a randomized study. 2007 Am. J. Transplant. pmid:17908280
Tricot L et al. Safety and efficacy of raltegravir in HIV-infected transplant patients cotreated with immunosuppressive drugs. 2009 Am. J. Transplant. pmid:19519819
Kofler S et al. Proton pump inhibitors reduce mycophenolate exposure in heart transplant recipients-a prospective case-controlled study. 2009 Am. J. Transplant. pmid:19519820
Barbas AS et al. Posterior reversible encephalopathy syndrome independently associated with tacrolimus and sirolimus after multivisceral transplantation. 2013 Am. J. Transplant. pmid:23331705
Gatault P et al. Reduction of Extended-Release Tacrolimus Dose in Low-Immunological-Risk Kidney Transplant Recipients Increases Risk of Rejection and Appearance of Donor-Specific Antibodies: A Randomized Study. 2017 Am. J. Transplant. pmid:27862923